Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up - Still a Buy?

Key Points

• Chugai Pharmaceutical's shares opened significantly higher at $24.60 after previously closing at $22.57, with the latest trading at $22.59.
• The company reported $0.20 earnings per share for the last quarter, with a revenue of $2.01 billion and a net margin of 33.08%.
• Chugai Pharmaceutical has a market cap of $74.34 billion and a price-to-earnings ratio of 28.60.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $22.57, but opened at $24.60. Chugai Pharmaceutical shares last traded at $22.59, with a volume of 1,568 shares trading hands.

Chugai Pharmaceutical Stock Up 0.1%

The stock has a market cap of $74.34 billion, a price-to-earnings ratio of 28.60 and a beta of 0.65. The business's fifty day moving average is $22.91 and its two-hundred day moving average is $24.57.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. The firm had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. As a group, sell-side analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.